Literature DB >> 6979616

The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man.

S C Jones, A Alavi, D Christman, I Montanez, A P Wolf, M Reivich.   

Abstract

Bladder and brain time-activity measurements in humans were performed after the intravenous administration of 2-[F-18]fluoro-2-deoxy-D-glucose. Radiation doses were calculated using the MIRD schema. The bladder wall received an average of 440 mrad/mCi (s.e. 76) in ten subjects who voided at 2 hr after administration of tracer. If these subjects had voided at 1 hr, the bladder-wall dose would have been reduced to 220 mrad/mCi. The brain received an average of 81 mrad/mCi in eight subjects. The doses to other organs, calculated from published dog biodistribution data, are between 50 and 85 mrad/mCi except for spleen and heart, which both received 160 mrad/mCi. These time-activity measurements for the critical organ in the human avoid the assumptions made in using animal biodistribution data for human dosimetry calculations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979616

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Estimates of the effective dose equivalent, HE, in positron emission tomography studies.

Authors:  W Huda; G A Sandison
Journal:  Eur J Nucl Med       Date:  1990

2.  Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)spiperone.

Authors:  H Herzog; H H Coenen; T Kuwert; K J Langen; L E Feinendegen
Journal:  Eur J Nucl Med       Date:  1990

3.  Quantitative and Visual Assessments toward Potential Sub-mSv or Ultrafast FDG PET Using High-Sensitivity TOF PET in PET/MRI.

Authors:  Spencer C Behr; Emma Bahroos; Randall A Hawkins; Lorenzo Nardo; Vahid Ravanfar; Emily V Capbarat; Youngho Seo
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

4.  Estimation of organ biodistribution and absorbed dose from external measurement with TLDs in PET studies.

Authors:  M Matsumoto; T Nakamura; H Watabe; M Itoh; J Hatazawa
Journal:  Med Biol Eng Comput       Date:  1993-07       Impact factor: 2.602

5.  Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose.

Authors:  Lawrence Oliver Dierickx; Eric Huyghe; Daniela Nogueira; Slimane Zerdoud; Thomas Filleron; Séverine Brillouet; Boris Delauney; Jacques Montagut; Louis Bujan; Pierre Plante; Frédéric Courbon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-10       Impact factor: 9.236

6.  Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.

Authors:  Jamshid Maddahi; Frank Bengel; Johannes Czernin; Paul Crane; Magnus Dahlbom; Heinrich Schelbert; Richard Sparks; Michael Phelps; Joel Lazewatsky
Journal:  J Nucl Cardiol       Date:  2018-11-28       Impact factor: 5.952

7.  PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs).

Authors:  G J Meyer; S L Waters; H H Coenen; A Luxen; B Maziere; B Langström
Journal:  Eur J Nucl Med       Date:  1995-12

8.  Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.

Authors:  J M Rozental; J D Cohen; M P Mehta; R L Levine; J M Hanson; R J Nickles
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

9.  Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Authors:  Ya-Yao Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Hanna Ng; Jon C Mirsalis; Ying-Kai Fu; Tieh-Chi Chu; Wen-Sheng Huang; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

10.  RadNuc: a graphical user interface to deliver dose rate patterns encountered in nuclear medicine with a 137Cs irradiator.

Authors:  Jordan B Pasternack; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-12-21       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.